Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 2018;392(10143):232-243 doi: S0140-6736(18)31364-3
Scientific Publications
- PMID: 30047376
- Title: Evaluation of a mosaic HIV 1 vaccine in a multicentre randomised double blind placebo controlled phase 1 2a clinical trial APPROACH and in rhesus monkeys NHP 13 19
- Abstract: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and preclinical studies. We aimed to evaluate mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel studies in humans and rhesus monkeys to define the optimal vaccine regimen to advance into clinical efficacy trials.
- Date: 1970-08-21
- Year: 2018
- Journal: Lancet
- PMID Author: Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H
- IAVI Topics: HIV Challenge Studies, HIV Vaccine Immunology
Evaluation of a mosaic HIV 1 vaccine in a multicentre randomised double blind placebo controlled phase 1 2a clinical trial APPROACH and in rhesus monkeys NHP 13 19
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
